Detalhe da pesquisa
1.
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
J Transl Med
; 21(1): 753, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880788
2.
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
BMC Cancer
; 23(1): 166, 2023 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36805683
3.
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
Future Oncol
; 19(30): 2017-2027, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665297
4.
Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Support Care Cancer
; 31(9): 518, 2023 Aug 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37572133
5.
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma.
Br J Cancer
; 126(10): 1450-1456, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35301436
6.
Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.
Br J Dermatol
; 187(1): 105-114, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35141876
7.
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Br J Dermatol
; 187(6): 981-987, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976170
8.
Circulating Tumour DNA in Melanoma-Clinic Ready?
Curr Oncol Rep
; 24(3): 363-373, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133615
9.
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Lancet Oncol
; 22(6): 836-847, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989557
10.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 643-654, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857412
11.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 655-664, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857414
12.
Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
Int J Cancer
; 149(11): 1926-1934, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310716
13.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658430
14.
Patient engagement in melanoma research: from bench to bedside.
Future Oncol
; 17(28): 3705-3716, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34213356
15.
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
Oncologist
; 25(1): 55-63, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292268
16.
Emergency ambulatory outpatient management of immune-mediated hypophysitis.
Support Care Cancer
; 28(9): 3995-3999, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564193
17.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345627
18.
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.
Br J Cancer
; 119(7): 793-800, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30033445
19.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Lancet
; 390(10105): 1853-1862, 2017 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28822576
20.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med
; 372(1): 30-9, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25399551